KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash & Equivalents: 2012-2024

Historic Cash & Equivalents for Xenon Pharmaceuticals (XENE) over the last 12 years, with Dec 2024 value amounting to $754.4 million.

  • Xenon Pharmaceuticals' Cash & Equivalents rose 533.70% to $555.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $555.3 million, marking a year-over-year increase of 533.70%. This contributed to the annual value of $754.4 million for FY2024, which is 407.53% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Cash & Equivalents of $754.4 million as of FY2024, which was up 407.53% from $148.6 million recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Cash & Equivalents registered a high of $754.4 million during FY2024, and its lowest value of $45.0 million during FY2020.
  • In the last 3 years, Xenon Pharmaceuticals' Cash & Equivalents had a median value of $148.6 million in 2023 and averaged $320.1 million.
  • In the last 5 years, Xenon Pharmaceuticals' Cash & Equivalents plummeted by 67.42% in 2022 and then skyrocketed by 407.53% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' Cash & Equivalents (Yearly) stood at $45.0 million in 2020, then soared by 290.34% to $175.7 million in 2021, then plummeted by 67.42% to $57.2 million in 2022, then spiked by 159.67% to $148.6 million in 2023, then surged by 407.53% to $754.4 million in 2024.